Press Releases

Investor Alerts

Feb 14, 2019

Satsuma Pharmaceuticals Announces Presentations at Upcoming Investor Conferences
Jan 5, 2017

Satsuma Pharmaceuticals Spins Out from Shin Nippon Biomedical Laboratories (SNBL) with Funding from Leading Institutional Life Science Investors

-- $12 Million Series A financing supports development of best-in-class therapy for acute migraine that incorporates novel and proprietary SNBL nasal drug delivery technology --

Show per page